Spectranetics acquires balloon catheter company

Spectranetics Corp. and AngioScore penned a $230 million deal to serve the peripheral and coronary markets by making AngioScore a wholly owned subsidiary of Spectranetics.   

Spectranetics reported that it will pay $115 million in cash and $115 million in stock to complete the transaction, which is expected be final by the end of June.

AngioScore, of Freemont, Calif., develops, makes and markets specialty balloon catheters to be used in the treatment of coronary and peripheral artery diseases. Colorado Springs, Colo.-based Spectranetics offers minimally invasive laser technologies for vascular treatments, ablation catheters and cardiac lead management devices.

Candace Stuart, Contributor

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup